Subscribe

The Mechanism of Action of CDK4/6 Inhibitors

Breast Cancer, SABCS Highlights
Videos — January 10, 2018

Featuring:

Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.

Related Articles

Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer
By Phoebe Starr
ASCO 2023 Highlights, Breast Cancer
August 2023, Vol 14, No 4
Read Article
FDA Expands Indication for Verzenio as Adjuvant Treatment for HR-Positive, HER2-Negative, Early Breast Cancer
FDA Approvals, News & Updates, Breast Cancer
April 2023, Vol 14, No 2
Read Article
Trodelvy Now Approved for Pretreated Patients with HR-Positive, HER2-Negative Breast Cancer
FDA Approvals, News & Updates, Breast Cancer
April 2023, Vol 14, No 2
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.